McClain to Hold Hearing on FDA Refusal to Regulate Hemp and CBD Products

WASHINGTON—Subcommittee on Health Care and Financial Services Chairwoman Lisa McClain (R-Mich.) today announced a hearing titled “Hemp in the Modern World: The Yearslong Wait for FDA Action” to examine the Food and Drug Administration (FDA)’s failure to regulate hemp-derived and cannabidiol (CBD) products under existing authorities for years.

“The FDA has failed for too long to do its job to ensure the safety of legalized hemp-derived products. Without these regulations, dangerous products could make their way to the shelves while safe and credible CBD products could be prevented from entering the market. We are going to investigate why exactly the FDA has decided to ignore their regulation responsibilities related to CBD and other areas of jurisdiction. We need to ensure that the FDA is not setting what would be a dangerous precedent and using this as an opportunity to seek more authority and resources from Congress,” said Chairwoman McClain.

WHAT: Hearing titled “Hemp in the Modern World: The Yearslong Wait for FDA Action”

DATE: Thursday, July 27, 2023

TIME: 2:00 PM ET

LOCATION: 2247 Rayburn House Office Building

WITNESSES:

• Jonathan S. Miller, General Counsel, U.S. Hemp Roundtable
• Rayetta G. Henderson, Ph.D., Senior Managing Scientist, ToxStrategies, LLC
• Richard A. Badaracco, President-Elect, Kentucky Narcotic Officers Association, (Retired) Assistant Special Agent in Charge, U.S. Drug Enforcement Administration

The hearing will be open to the public and press and will be livestreamed online at https://oversight.house.gov/.